Rada Savic, PhD
Professor
Bioengineering
School of Pharmacy

By integrating multi-scale, and multi-level clinical data, we aim to determine the right dose, schedule, and treatment duration of various therapies, potentially bringing novel, precise and personalized treatment options to patients with unmet need more quickly.

• Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Solans BP, Béranger A, Radtke K, Mohamed A, Mirzayev F, Gegia M, Linh NN, Schumacher SG, Nahid P, Savic RM
• Interplay among malnutrition, chemoprevention, and the risk of malaria in young Ugandan children: Longitudinal pharmacodynamic and growth analysis.
  CPT: pharmacometrics & systems pharmacology 2023 Ali AM, Wallender E, Hughes E, Dorsey G, Savic RM
• A comparison of clinical development pathways to advance tuberculosis regimen development.
  BMC infectious diseases 2022 Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM
• Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Garcia-Cremades M, Vucicevic K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM
• Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Hughes JA, Solans BP, Draper HR, Schaaf HS, Winckler JL, van der Laan L, Radtke KK, Fourie B, Wiesner L, Hesseling AC, Savic RM, Garcia-Prats AJ
• Examining nonadherence in the treatment of tuberculosis: The patterns that lead to failure.
  British journal of clinical pharmacology 2022 Fox WS, Strydom N, Imperial MZ, Jarlsberg L, Savic RM
• Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM
• Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Hughes E, Wallender E, Kajubi R, Jagannathan P, Ochieng T, Kakuru A, Kamya MR, Clark TD, Rosenthal PJ, Dorsey G, Aweeka F, Savic RM
• Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.
  Pharmaceutics 2022 Garcia-Cremades M, Hendrix CW, Jayachandran P, Strydom N, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM
• Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
  Antimicrobial agents and chemotherapy 2022 Yun HY, Chang MJ, Jung H, Chang V, Wang Q, Strydom N, Yoon YR, Savic RM
• Pharmacometrics in tuberculosis: progress and opportunities.
  International journal of antimicrobial agents 2022 Wilkins JJ, Svensson EM, Ernest JP, Savic RM, Simonsson USH, McIlleron H
• Clinical standards for the dosing and management of TB drugs.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 Alffenaar JWC, Stocker SL, Forsman LD, Garcia-Prats A, Heysell SK, Aarnoutse RE, Akkerman OW, Aleksa A, van Altena R, de Oñata WA, Bhavani PK, Van't Boveneind-Vrubleuskaya N, Carvalho ACC, Centis R, …
• Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Imperial MZ, Nedelman JR, Conradie F, Savic RM
• Drug concentration at the site of disease in children with pulmonary tuberculosis.
  The Journal of antimicrobial chemotherapy 2022 Lopez-Varela E, Abulfathi AA, Strydom N, Goussard P, van Wyk AC, Demers AM, Deventer AV, Garcia-Prats AJ, van der Merwe J, Zimmerman M, Carter CL, Janson J, Morrison J, Reuter H, Decloedt EH, Seddon …
• Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, …
• Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Radtke KK, Hesseling AC, Winckler JL, Draper HR, Solans BP, Thee S, Wiesner L, van der Laan LE, Fourie B, Nielsen J, Schaaf HS, Savic RM, Garcia-Prats AJ
• Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
  CPT: pharmacometrics & systems pharmacology 2022 Green ML, Savic RM, Tonda M, Jorga K, Washington CB
• Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
  CPT: pharmacometrics & systems pharmacology 2022 Savic RM, Green ML, Jorga K, Zager M, Washington CB
• Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis.
  Expert review of clinical pharmacology 2022 Radtke KK, Svensson EM, van der Laan LE, Hesseling AC, Savic RM, Garcia-Prats AJ
• A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.
  Antimicrobial agents and chemotherapy 2022 Kaya F, Ernest JP, LoMauro K, Gengenbacher M, Madani A, Aragaw WW, Zimmerman MD, Sarathy JP, Alvarez N, Daudelin I, Wang H, Lanni F, Weiner DM, Via LE, Barry CE, Olivier KN, Dick T, Podell BK, Savic …
• Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.
  Open forum infectious diseases 2021 Yun HY, Chang V, Radtke KK, Wang Q, Strydom N, Chang MJ, Savic RM
• Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
  American journal of respiratory and critical care medicine 2021 Imperial MZ, Phillips PPJ, Nahid P, Savic RM
• Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment.
  Annual review of pharmacology and toxicology 2021 Garcia-Cremades M, Solans BP, Strydom N, Vrijens B, Pillai GC, Shaffer C, Thomas B, Savic RM
• A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.
  Trials 2021 Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ
• Is Glycemic Control the Secret to Tuberculosis Control?
  American journal of respiratory and critical care medicine 2021 Huddart S, Savic RM, Cattamanchi A
• Optimising pyrazinamide for the treatment of tuberculosis.
  The European respiratory journal 2021 Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE, …
• Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.
  Antimicrobial agents and chemotherapy 2021 Ernest JP, Sarathy J, Wang N, Kaya F, Zimmerman MD, Strydom N, Wang H, Xie M, Gengenbacher M, Via LE, Barry CE, Carter CL, Savic RM, Dartois V
• Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis.
  Antimicrobial agents and chemotherapy 2021 Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, Nsubuga P, Dorman S, Weiner M, Savic RM, Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention
• Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.
  The Journal of infectious diseases 2021 Bigelow KM, Deitchman AN, Li SY, Barnes-Boyle K, Tyagi S, Soni H, Dooley KE, Savic RM, Nuermberger EL
• Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.
  Nature communications 2021 Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang …
• Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
  The New England journal of medicine 2021 Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH,…
• Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
  Clinical pharmacology and therapeutics 2021 Hughes E, Wallender E, Mohamed Ali A, Jagannathan P, Savic RM
• Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.
  Clinical and translational science 2021 Vora B, Brackman DJ, Zou L, Garcia-Cremades M, Sirota M, Savic RM, Giacomini KM
• Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer.
  Drugs in R&D 2021 Jayachandran P, Knox SJ, Garcia-Cremades M, Savic RM
• Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021 Garcia-Prats AJ, Salazar-Austin N, Conway JH, Radtke K, LaCourse SM, Maleche-Obimbo E, Hesseling AC, Savic RM, Nachman S
• Visualizing the dynamics of tuberculosis pathology using molecular imaging.
  The Journal of clinical investigation 2021 Ordonez AA, Tucker EW, Anderson CJ, Carter CL, Ganatra S, Kaushal D, Kramnik I, Lin PL, Madigan CA, Mendez S, Rao J, Savic RM, Tobin DM, Walzl G, Wilkinson RJ, Lacourciere KA, Via LE, Jain SK
• Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
  The Journal of antimicrobial chemotherapy 2021 Weiner M, Gelfond J, Johnson-Pais TL, Engle M, Johnson JL, Whitworth WC, Bliven-Sizemore E, Nsubuga P, Dorman SE, Savic R, Pharmacokinetics/Pharmacodynamics Group of Tuberculosis Trials Consortium
• A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.
  CPT: pharmacometrics & systems pharmacology 2021 Jayachandran P, Garcia-Cremades M, Vucicevic K, Bumpus NN, Anton P, Hendrix C, Savic R
• Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data.
  Pharmaceuticals (Basel, Switzerland) 2021 Kang WH, Lee JY, Chae JW, Lee KR, Baek IH, Kim MS, Back HM, Jung S, Shaffer C, Savic R, Yun HY
• Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.
  The European respiratory journal 2021 Radtke KK, Hibma JE, Hesseling AC, Savic RM
• Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
  Antimicrobial agents and chemotherapy 2020 Hughes E, Imperial M, Wallender E, Kajubi R, Huang L, Jagannathan P, Zhang N, Kakuru A, Natureeba P, Mwima MW, Muhindo M, Mwebaza N, Clark TD, Opira B, Nakalembe M, Havlir D, Kamya M, Rosenthal PJ, …
• Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
  American journal of respiratory and critical care medicine 2020 Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM
• Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
  Clinical pharmacology and therapeutics 2020 Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, Zheng JH, Cook J
• Mathematical model and tool to explore shorter multi-drug therapy options for active pulmonary tuberculosis.
  PLoS computational biology 2020 Fors J, Strydom N, Fox WS, Keizer RJ, Savic RM
• Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
  Annual review of pharmacology and toxicology 2020 Ernest JP, Strydom N, Wang Q, Zhang N, Nuermberger E, Dartois V, Savic RM
• Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".
  Clinical pharmacology and therapeutics 2020 Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Savic RM
• Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
  Clinical pharmacology and therapeutics 2020 Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, Luetkemeyer AF, Savic RM
• Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.
  Antimicrobial agents and chemotherapy 2020 Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Jean Francois D, Zimmerman M, Kaya F, Zhang N, Saito K, Ocheretina O, Savic R, Dartois V, Johnson WD, Pape JW, Nathan C, Fitzgerald DW
• Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
  Journal of acquired immune deficiency syndromes (1999) 2020 Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM
• Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
  The lancet. HIV 2020 Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA, Wolf L, Sebe M, Likoti M, Fyvie MJ, Shibambo I, Beattie T, Chaisson RE, Churchyard GJ, DOLPHIN Study Team
• Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
  Antimicrobial agents and chemotherapy 2020 Zhang N, Strydom N, Tyagi S, Soni H, Tasneen R, Nuermberger EL, Savic RM
• The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.
  PLoS medicine 2019 Vernon A, Fielding K, Savic R, Dodd L, Nahid P
• Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer.
  Translational oncology 2019 Knox SJ, Jayachandran P, Keeling CA, Stevens KJ, Sandhu N, Stamps-DeAnda SL, Savic R, Shura L, Buyyounouski MK, Grimes K
• Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.
  The Lancet. Child & adolescent health 2019 Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM
• Accuracy of point-of-care ultrasound by pediatric emergency physicians for testicular torsion.
  Journal of pediatric urology 2019 Friedman N, Pancer Z, Savic R, Tseng F, Lee MS, Mclean L, Bagli DJ, Tessaro MO
• Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
  PLoS medicine 2019 Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM
• Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
  PLoS medicine 2019 Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM
• Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
  Antimicrobial agents and chemotherapy 2019 Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V
• Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
  PLoS medicine 2019 Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE, Zimmerman M, Dartois V, Savic RM
• Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
  Antimicrobial agents and chemotherapy 2019 Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM
• Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
  Nature medicine 2019 Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM
• High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types.
  eLife 2018 Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ, Savic RM, Prideaux B, Dartois V
• A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
  Nature medicine 2018 Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM
• Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.
  Clinical pharmacology and therapeutics 2018 Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM
• Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT
• Impact of immunopathology on the antituberculous activity of pyrazinamide.
  The Journal of experimental medicine 2018 Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V
• Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
  Science translational medicine 2018 Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE
• Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
  The Journal of infectious diseases 2018 Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM
• Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
  Clinical pharmacology and therapeutics 2018 Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM
• Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
  Antimicrobial agents and chemotherapy 2018 Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC
• Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.
  Clinical pharmacokinetics 2017 Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  Breast cancer research : BCR 2017 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, …
• Tuberculous meningitis.
  Nature reviews. Neurology 2017 Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE, Tuberculous Meningitis International Research Consortium
• New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.
  Clinical and translational science 2017 Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM
• Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
  Antimicrobial agents and chemotherapy 2017 Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA, Tuberculosis Trials Consortium
• Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
  Clinical pharmacology and therapeutics 2017 Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE, Tuberculosis Trials Consortium of the Centers for Disease Control…
• Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.
  CPT: pharmacometrics & systems pharmacology 2017 Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Pérez Ruixo JJ, Plan EL, Savic R, van Hasselt JG, Weber B, Zhou C, Comets E, Mentré F, Model …
• Importance of Drug Pharmacokinetics at the Site of Action.
  Clinical and translational science 2017 Rizk ML, Zou L, Savic RM, Dooley KE
• Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
  The Lancet. Haematology 2016 Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer…
• Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.
  Journal of clinical microbiology 2016 Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P
• A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.
  Clinical pharmacology and therapeutics 2016 Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic RM
• The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
  Clinical pharmacokinetics 2016 Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM
• A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
  PloS one 2016 Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE
• GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, Thwaites GE, Boulware DR, Tuberculous Meningitis International Research Consortium
• Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.
  Pharmaceutical research 2016 Larsen MS, Keizer R, Munro G, Mørk A, Holm R, Savic R, Kreilgaard M
• Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M,…
• Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.
  The lancet. HIV 2015 Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR
• Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
  Clinical pharmacology and therapeutics 2015 Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE
• Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
  Malaria journal 2015 Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F
• Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives.
  ACS infectious diseases 2015 Via LE, Savic R, Weiner DM, Zimmerman MD, Prideaux B, Irwin SM, Lyon E, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Dutta NK, Shim T, Cho JS, Kim W, Karakousis PC, Lenaerts A, Nuermberger E, Barry CE…
• Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
  Therapeutic drug monitoring 2015 Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC
• Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.
  Antimicrobial agents and chemotherapy 2015 Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW, ACTG A5311 Study Team
• The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
  The Pediatric infectious disease journal 2015 Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F
• Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
  American journal of respiratory and critical care medicine 2015 Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M, …
• Designing drug trials: considerations for pregnant women.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M
• Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
  Journal of acquired immune deficiency syndromes (1999) 2014 Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF
• Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
  Antimicrobial agents and chemotherapy 2014 Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team
• Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.
  Clinical pharmacology and therapeutics 2014 Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, Maeda S, Simpson MD, Hedderson MM, Davis RL, Roden DM, Giacomini KM, Savic RM
• Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
  Antimicrobial agents and chemotherapy 2014 Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE
• Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.
  Journal of the Pediatric Infectious Diseases Society 2014 Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME, Tuberculosis Trials …
• Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
  Journal of clinical pharmacology 2013 Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F
• Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013 Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J
• Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).
  Journal of pharmaceutical sciences 2013 Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM
• Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
  Clinical pharmacology and therapeutics 2012 Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F, ANRS 134–COPHAR 3 Study Group
• The pharmacokinetics of oxypurinol in people with gout.
  British journal of clinical pharmacology 2012 Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO
• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.
  The Lancet. Infectious diseases 2012 Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C, participants of Conference on Antiretroviral Drug Optimization
• Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.
  Journal of pharmacokinetics and pharmacodynamics 2012 Delattre M, Savic RM, Miller R, Karlsson MO, Lavielle M
• Standard Error of Empirical Bayes Estimate in NONMEM® VI.
  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2012 Kang D, Bae KS, Houk BE, Savic RM, Karlsson MO
• Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.
  Journal of pharmacokinetics and pharmacodynamics 2010 Baverel PG, Savic RM, Karlsson MO
• Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.
  The AAPS journal 2010 Savic RM, Mentré F, Lavielle M
• Evaluation of an extended grid method for estimation using nonparametric distributions.
  The AAPS journal 2009 Savic RM, Karlsson MO
• Performance in population models for count data, part II: a new SAEM algorithm.
  Journal of pharmacokinetics and pharmacodynamics 2009 Savic R, Lavielle M
• Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.
  The AAPS journal 2009 Savic RM, Karlsson MO
• Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
  Journal of pharmacokinetics and pharmacodynamics 2009 Baverel PG, Savic RM, Wilkins JJ, Karlsson MO
• Semiparametric distributions with estimated shape parameters.
  Pharmaceutical research 2009 Petersson KJ, Hanze E, Savic RM, Karlsson MO
• Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.
  The AAPS journal 2009 Carlsson KC, Savic RM, Hooker AC, Karlsson MO
• Evaluation of the nonparametric estimation method in NONMEM VI.
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2008 Savic RM, Kjellsson MC, Karlsson MO
• Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.
  Antimicrobial agents and chemotherapy 2008 Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US
• Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
  Journal of pharmacokinetics and pharmacodynamics 2007 Savic RM, Jonker DM, Kerbusch T, Karlsson MO
• Diagnosing model diagnostics.
  Clinical pharmacology and therapeutics 2007 Karlsson MO, Savic RM
• Population Pharmacokinetic Analysis of the Oral Absorption Process of Tacrolimus in Healthy Volunteers
  Kor J Clin Pharmacol Ther 2007 Hong EU, Savic RM and Yim DS
• Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.
  Journal of clinical pharmacology 2006 Osterberg O, Savic RM, Karlsson MO, Simonsson US, Nørgaard JP, Walle JV, Agersø H
• Application of population pharmacokinetics to cladribine.
  BMC pharmacology 2005 Lindemalm S, Savic RM, Karlsson MO, Juliusson G, Liliemark J, Albertioni F